Latest From NoNO Inc.
Hopes that a neuroprotective agent can be developed to reduce the damage caused by ischaemic stroke have received a boost, with data from a Phase II trial in the The Lancet Neurology showing promise for a protein acting on a post-synaptic brain protein. Together with some promising early data for two other potential neuroprotective agents, experts say the data seem to support renewed efforts in developing such drugs despite their chequered developmental history.
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- NoNO Inc.
- Senior Management
- Michael Tymianski, MD, PhD, Pres.
- Contact Info
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.